Drug Price Transparency
Mar 16, 2022
AHA shares proposals to lower Medicare drug prices with congress.
Nov 2, 2021
The Purchaser Business Group on Health (PBGH), a coalition of about 40 large private and public employers including Walmart, Disney, Costco and Microsoft, recently launched EmsanaRx, a nonprofit PBM. Meanwhile, billionaire Mark Cuban’s Cost Plus Drug Company is another PBM that launched recently.
Sep 30, 2021
Our shared focus with Congress and Administration is on providing relief from the pandemic, ensuring a smooth recovery, and rebuilding a better health care system for the future. The American Hospital Association continues to incorporate principles that promote improved affordability, value, and…
Jul 14, 2021
The Senate Judiciary Committee Subcommittee on Competition Policy, Antitrust, and Consumer Rights held a hearing on surging drug prices and anticompetitive conduct in the pharmaceutical industry.
Jul 6, 2021
The AHA July 2 expressed support for the Drug-Price Transparency for Consumers Act of 2021 (S.2304).
Sep 14, 2020
A new study demonstrates the cost to the U.S. health care system from an anti-competitive tactic known as “product hopping,” which involves a brand name drug company moving patients to a new reformulated version of a drug when an existing drug’s exclusivity is close to expiring.
Oct 9, 2019
The California Office of Statewide Health Planning and Development recently released the nation’s first mandatory data on wholesale acquisition cost increases for prescription drugs.
Sep 10, 2019
A recent report from UnitedHealth comparing specialty drug spending in hospitals and independent physician offices fails to account for critical differences between these two settings while also ignoring the chief culprit in the growth in drug spending – the drug companies themselves.
Jul 17, 2019
The House Energy and Commerce Committee today approved legislation to address surprise medical bills and Medicaid disproportionate share hospital cuts.
Jul 9, 2019
A federal judge yesterday struck down a Centers for Medicare & Medicaid Services final rule requiring drug companies to include list prices in direct-to-consumer television advertisements of products for which Medicare and Medicaid reimbursement is available.